An experimental vaccine has been shown to protect mice against tuberculosis (TB) and may eventually be suitable for treating human infants living with HIV, a group unable to use the existing TB vaccine, according to a National Institutes of Health (NIH) statement. In a new study, researchers genetically modified a close relative of Mycobacterium tuberculosis, the bacterium that causes TB. The existing Bacille Calmette-Guerin vaccine can cause severe TB infection in HIV-positive infants. The study was funded by the National Institute of Allergy and Infectious Diseases and was published in the journal Nature Medicine.

To read the NIH statement, click here.